Clinical trial · Interventional
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
A Comparative Study of Al18F-NOTA-LM3 Versus 68Ga-DOTATATE PET/CT for Tumor Detection in Patients With Pheochromocytoma and Paraganglioma
NCT07288931CI-TRIAL-00099119recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-LM3 PET/CT and compare it with 68Ga-DOTATATE PET/CT in patients with pheochromocytoma/paraganglioma (PPGL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pheochromocytoma/Paraganglioma (PPGL) | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic Test: 68Ga-DOTATATE | Drug | — | UNRESOLVED |
| Diagnostic Test: Al18F-NOTA-LM3 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Al18F-NOTA-LM3 and 68Ga-DOTATATE PET/CT scan
- description
- Patients will perform an Al18F-NOTA-LM3 PET/CT as well as a 68Ga-DOTATATE PET/CT scan within one week, with a minimum 24-hour interval between scans.
- interventionNames
- Drug: Diagnostic Test: Al18F-NOTA-LM3
- Drug: Diagnostic Test: 68Ga-DOTATATE
Primary outcomes (1)
- measure
- Tumor Detection Rate
- timeFrame
- From study completion to 6 months after completion.
- description
- Compare the number of tumor detected by Al18F-NOTA-LM3 PET/CT and 68Ga-DOTATATE PET/CT
Secondary outcomes (1)
- measure
- Standardized Uptake Value (SUV) of Tumor
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 to 80 years. * Suspected or confirmed PPGL patients. Exclusion Criteria: * Combined with other types of tumors. * Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min). * Pregnant or breast-feeding women. * Inability to perform PET/CT scans.
References
Publications (0)
Data not yet available
No reference posted for this study.